Clinical Trials Logo

Filter by:
NCT ID: NCT00337103 Completed - Clinical trials for Metastatic Breast Cancer

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Start date: September 20, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.

NCT ID: NCT00335452 Completed - Angina Unstable Clinical Trials

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

CURRENT/OASIS7
Start date: June 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

NCT ID: NCT00332917 Completed - Clinical trials for Early Stage Parkinson's Disease

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial

NCT ID: NCT00332891 Completed - Anxiety Disorders Clinical Trials

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

ELECTRA
Start date: March 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to placebo in patients with generalized anxiety disorder (GAD). The secondary objectives are to evaluate the efficacy of SR58611A on disability and quality of life in patients with GAD and to evaluate safety of SR58611A

NCT ID: NCT00331838 Completed - Clinical trials for Venous Thromboembolism

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

TREK
Start date: May 2006
Phase: Phase 2
Study type: Interventional

The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery. Secondary objectives were to evaluate the safety (incidence of major bleeding) of AVE5026, to document the efficacy and safety of AVE5026 post-operative regimens, and to assess the pharmacokinetic parameters of AVE5026.

NCT ID: NCT00331149 Completed - Parkinson Disease Clinical Trials

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Start date: June 20, 2006
Phase: Phase 3
Study type: Interventional

This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries. The new prolonged release formulation allows the drug to be taken once a day rather than three times a day. This study will also evaluate the side effects of the new prolonged release formulation of ropinirole

NCT ID: NCT00329238 Completed - Thromboembolism Clinical Trials

Secondary Prevention of Venous Thrombo Embolism (VTE).

RE-MEDY
Start date: May 2006
Phase: Phase 3
Study type: Interventional

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.

NCT ID: NCT00328627 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

NCT ID: NCT00322595 Completed - Clinical trials for Generalized Anxiety Disorder

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

SILVER
Start date: May 2006
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00320385 Completed - Neoplasms, Breast Clinical Trials

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.